Prof. Dr. Ayça Sayı Yazgan secured funding for her project through the TÜBİTAK Center of Excellence Support Program. Within the framework of the TÜBİTAK Center of Excellence Support Program (1004 Program), the project titled "Development of an OMV-based H. pylori Vaccine Prototype" received support under the guidance of Prof. Dr. Ayça Sayı Yazgan. Dr. Sümeyye Akçelik Deveci, Dr. Mehmet Karaçay, MSc. Bahar Deniz, and Res. Assis. Zeynep Nur Şentürk will be conducting experiments in her Molecular Immunology Lab. Additionally, Prof. Dr. İhsan Gürsel (Izmir Biomedicine and Genome Center), Assist. Prof. Sinem Öktem Okullu (Acibadem University), and Assist. Prof. Banu Bayyurt (Middle East Technical University) are involved in the project as researchers.

The Protection and Treatment National Platform, spearheaded by the Izmir Biomedicine and Genome Center (IBG), encompasses various universities and industrial organizations alongside our university. This includes Middle East Technical University, Dokuz Eylül University, Ege University, Selçuk University, ATABAY KİMYA SAN. VE TİC. AŞ., PETROYAĞ VE KİMYASALLARI SAN. VE TİC. AŞ.

Gastric cancer stands as the leading cause of death among cancer types globally. Helicobacter pylori (H. pylori) has been identified as a significant risk factor for gastric cancer development. In countries like Turkiye, 80% of individuals are infected with H. pylori, yet only 20% of them experience gastric complications such as gastritis, ulcers, or gastric cancer. Through this project, Prof. Dr. Ayça Sayı Yazgan and collaborating researchers aim to develop an advanced-phase H. pylori vaccine prototype. Following the completion of these studies, the goal is to create a preventive prophylactic vaccine for distribution in other developing countries worldwide.